NIH PAR · RMOD · X01
PAR-27-071: Discovery of the Genetic Basis of Childhood Cancers and of Congenital Anomalies: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First Program), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program supported genomic data generating centers. Applicants are encouraged to propose sequencing of existing pediatric cancer or congenital anomaly cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of congenital anomalies, to study the molecular basis of the associations between congenital anomalies and increased cancer risk, or to expand the range of pediatric disorders included within the Kids First Data…
- NOFO number
- PAR-27-071
- Type
- PAR
- Activity code
- X01
- Primary institute
- RMOD
- Clinical trials
- Not Allowed
- Posted
- Jun 18, 2026
- Opens
- Dec 11, 2026
- Expires
- Jan 12, 2027
PAR-27-071 due dates
1 application due date remains before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) |
|---|
| January 11th, 2027 |
Funded projects
NIH RePORTER lists no awards under PAR-27-071 in FY2022–FY2026. Awards usually appear a few months after the first review cycle.
Participating institutes
5 NIH institutes and offices take applications under PAR-27-071. Contact the program officer at the institute that fits your research before applying.
- RMOD
- NOFO
- NCI · National Cancer Institute
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
- none
Related notices
NIH lists no related notices for PAR-27-071 yet.
Award terms
- Application types allowed
- New The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Not applicable; there are no funds associated with a resource access award.
- Project period
- The scope of the proposed project should determine the project period. The maximum project period is 1 year. Investigators are expected to ship samples to designated Kids First Program's data generating center within 6 months of the award notification. This period may be extended only in exceptional cases upon justification and approval. NIH grants policies as described in the NIH Grants Policy…
- Funds available and number of awards
- Not applicable; there are no funds associated with a resource access award.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-082.
Other open NOFOs for X01
- PAR-27-069Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens (X01 Clinical Trial Not Allowed)PM · next due Oct 30, 2026
- PAR-25-437Environmental influences on Child Health Outcomes (ECHO) Cohort Data and Biospecimen Access (X01 Clinical Trial Not Allowed)ECHO · next due Nov 4, 2026
- PAR-27-111Biological Testing Facility for Contraception & Reproductive Health (X01 Clinical Trial Not Allowed)NICHD · next due Jan 4, 2027
- PAR-25-447NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)NHLBI · next due Feb 8, 2027
- PAR-27-051NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed)NIDA · next due Apr 15, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.